2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6254 Association between burn pit exposure and incident lymphoid neoplasms in US veterans enrolled in the VA airborne hazards and open burn pit registry (AHOBPR)

Ravand Samaeekia, MD, Kim Abbegail Tan Aldecoa, MD2, Jia Yin Wan, M.S.3, Jimmy H. Yao, MD4, Wendy Cozen, DO, MPH5, Pankaj Gupta, MD6, Helen Ma, MD, MS7
1 University of California, Irvine, Irvine, California, United States
2 University of California, Irvine, Irvine, California, United States
3 University of California, Irvine, Irvine, California, United States
4 University of California, Irvine, Irvine, California, United States
5 University of California, Irvine, Irvine, California, United States
6 University of California, Irvine, Irvine, California, United States, VA Long Beach Healthcare System, Long Beach, California, United States
7 University of California, Irvine, Irvine, California, United States, VA Long Beach Healthcare System, Long Beach, California, United States

Background

Burn pit exposure during deployment to the Middle East has been implicated as potentially carcinogenic; however, its association with lymphoid neoplasms remains uncertain. Prior epidemiologic studies have largely relied on deployment location or duration as exposure surrogates rather than burn-pit specific cumulative exposure. We evaluated whether cumulative burn pit exposure was associated with incident non-Hodgkin lymphoma (NHL), plasma cell neoplasms (PCN), and Hodgkin lymphoma (HL) using the Veteran Affairs (VA) Airborne Hazards and Open Burn Pit Registry (AHOBPR) linked to VA electronic health records.

 

Methods

We studied a retrospective cohort of Veterans enrolled in the AHOPBR with available cumulative burn pit exposure data linked to longitudinal VA medical records. Cumulative burn pit exposure was categorized as unexposed (0 days) or quartiles (Q) of the total number of exposure days. Outcomes included incident NHL (including Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, hairy cell leukemia, mantle cell lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, and mature T/NK-cell lymphomas), PCN (including multiple myeloma and plasmacytomas), and HL. Cases that were not otherwise specified or monoclonal gammopathy of undetermined significance (MGUS) were included in the cases and excluded from controls. Follow up was calculated from earliest deployment date to date of lymphoid neoplasm diagnosis, death, or last follow up. Multivariable Cox proportional hazards regression models were adjusted for age at deployment, sex, race and ethnicity, military branch, and smoking history to estimate the hazard ratios (HR) and corresponding 95% confidence intervals (CI).

 

Results

There were 244,238 Veterans included in the analysis. Most were male (n=218,015, 89%), White (n=162,179, 66%), and enlisted in the Army (n=152,348, 62%). Most Veterans were never smokers (n=146,863, 60%); 89,378 reported ever smoking (37%), and the tobacco history was unknown in 7,997 (3%). There were 444 cases of lymphoid neoplasms, with most being NHL (n=270, 61%), PCN (n=99, 22%), HL (n=54, 12%) with few NOS (n=14, 3%) and MGUS (n=7, 2%). The median follow up time was 19.9 years (interquartile range, 16.4-22.5 years). No dose-response relationship was observed between cumulative burn pit exposure and all incident lymphoid neoplasms combined (HR 0.34 [95% CI, 0.14-0.86], 0.33 [95% CI, 0.13-0.83], 0.37 [95% CI, 0.15-0.93], and 0.38 [95% CI, 0.15-0.96]) when comparing Q1-4 to unexposed Veterans, respectively.  Cumulative burn pit exposure was also not associated with increased risk of NHL, with HR 0.17 (95% CI, 0.06-0.49), 0.16 (95% CI, 0.06-0.45), 0.17 (95% CI, 0.06-0.47), and 0.21 (95% CI, 0.07-0.60) when comparing Q1-4 to unexposed Veterans, respectively. Similarly, there was no statistically significant increased risk between incident PCN and cumulative burn pit exposure: HR 1.64 (95% CI, 0.20-13.22), 0.97 (95% CI, 0.12-7.60), 1.52 (95% CI, 0.20-11.68), and 1.15 (95% CI, 0.14-9.36) when comparing Q1-4 to unexposed Veterans, respectively. Finally, no significant differences were observed in HL HR 1.46 (95% CI, 0.51-4.13), 1.32 (95% CI, 0.53-3.30), and 2.42 (95% CI, 0.79-7.40), and 1.00 (95% CI 1.00-1.00) from Q1-4 vs unexposed, respectively.

 

Conclusions

Using the VA AHOBPR of over 244,000 U.S. Veterans, self-reported individual-level cumulative burn pit exposure was not associated with a dose-dependent increase in the risk of developing lymphoid neoplasms, NHL, PCN, or HL. In the overall group and in NHL, the effect size of HRs decreased with increasing cumulative exposure suggesting a potential healthy “deployer” effect (as those with increasing exposure were also deployed longer) or another unmeasured confounder. Additional studies incorporating objective exposure assessment, latency analyses, and external comparison cohorts are needed to clarify the relationship between military burn pit exposure and lymphoid neoplasms.

Ravand Samaeekia, MD: No relevant conflicts of interest to declare.